Background: Radiolabeled iodine 131 therapy is used for treatment of multinodular toxic goiter, but longterm follow-up studies are lacking.
reduction in median thyroid volume from 56 mL (range, 21-430 mL) to 44 mL (range, 15-108 mL), representing a 24% reduction related to the insufficient 131 I dose. In all patients, the initial median thyroid volume of 44 mL (range, 16-430 mL) decreased to 25 mL (range, 8-120 mL) (PϽ.005), representing a median reduction of 43%, 24 months after the last 131 I dose. Hypothyroidism evaluated using life-table analysis developed in 6% of patients who did not receive antithyroid pretreatment and 20% who did (PϽ.005) after a median of 42 months (range, 3-60 months), the total hypothyroidism frequency being 14% within 5 years of treatment.
Conclusions: Ninety-two percent of patients with multinodular toxic goiter were cured with 1 or 2 treatments. The thyroid volume was reduced by 43%, with few side effects. Iodine 131 should be the choice of treatment in patients with multinodular toxic goiter.
Arch Intern Med. 1999; 159:1364 -1368 M ULTINODULAR goiter is a common cause of hyperthyroidism, especially in areas of mild to moderate iodine deficiency. 1 In these patients, hyperthyroidism cannot be expected to be permanently cured by antithyroid drug treatment. Radiolabeled iodine 131 therapy is in principle an attractive treatment modality, since the suppressed extranodular thyroid tissue is partly protected, and in recent years, the popularity of this treatment has increased. Therefore, it is of great importance to evaluate the long-term effects and possible side effects of this treatment. A 1-year follow-up of 70 patients was published from our department in 1986, demonstrating a 35% reduction of thyroid volume, and hypothyroidism developed in only 1 patient. 2 Studies evaluating the longterm effects of 131 I treatment in patients with Graves disease, [3] [4] [5] [6] [7] autonomously functioning solitary hot or toxic thyroid nodules, [8] [9] [10] [11] [12] and multinodular nontoxic goiter have been performed. [13] [14] [15] [16] However, few studies 6, 7, 17 have described the long-term effects of 131 I treatment in patients with multinodular toxic goiter, and a precise evaluation of the long-term changes in thyroid volume is not available.
We therefore wanted to evaluate the long-term changes in thyroid function and volume using a precise and accurate ultrasonic technique 18 in a large, prospective group of consecutive patients with multinodular toxic goiter treated with 131 I. We used an algorithm for 131 I dose calculation, taking volume and 24-hour 131 I uptake into consideration.
RESULTS
Clinical data for the 130 patients are given in Table 1 . The median follow-up was 72 months (12-180 months). Patients pretreated with antithyroid drugs did not differ significantly from those not receiving antithyroid pretreatment with regard to age, sex, 131 I dose, follow-up, or the proportion needing more than 1 131 I dose. The patients receiving antithyroid pretreatment had significantly lower FT 4 I and FT 3 I at the time of 131 I treatment than patients not receiving antithyroid pretreatment (Table 1) . Thyroid function variables before antithyroid pretreatment were not available in all patients and are therefore not given. The pretreated group had a significantly higher 24-hour 131 I uptake ( Table  1 ). The median initial thyroid volume was higher in the pretreated group (59 mL [16- 430 mL] vs 43 mL [18-125 mL] ), but the difference was not significant (P = .09; Table 1 ). However, comparing the initial volume in patients needing more than 1 131 I dose, a highly significant difference was seen (74 mL [21-430 mL] in the pretreated group vs 47 mL [23-125 mL] in the group not pretreated) (PϽ.005).
The median initial 131 I dose was 313 MBq (93-925 MBq), whereas the median total dose was 370 MBq (93-1850 MBq). More than 1 dose was given due to persistent hyperthyroidism in 41 patients and to reduce goiter size in 8.
The median time to become euthyroid after 131 I therapy was 5 weeks (range, 3 weeks to 24 months) after the last 131 I treatment ( Table 2 ). There were no significant differences between patients given antithyroid pretreatment and those who were not. Sixty-eight patients (52%) were euthyroid within 3 months after the first 131 I treatment. Eight patients did not become euthyroid after 131 I treatment. Three of these 8 patients had 1 131 I treatment, 4 patients had 2 treatments, and 1 patient had 3 treatments. These patients did not want subsequent 131 I treatment and were given longterm antithyroid drug treatment. *FT 4 I indicates free thyroxine index; FT 3 I, free triiodothyronine index. Unless otherwise indicated, data are given as median (range).
PATIENTS AND METHODS
The study population consisted of 130 consecutive patients treated with 131 I for a multinodular toxic goiter and observed for a minimum of 1 year. Sixty-six patients were pretreated with antithyroid drugs, whereas 64 were not. Another 15 patients were treated in this period but were unavailable for follow-up within 12 months (7 were given antithyroid pretreatment). The patients were seen from November 1, 1979, through April 31, 1994. Type of thyroid gland was determined using technetium Tc 99mpertechnetate scintigraphy and ultrasound, whereas the diagnosis of hyperthyroidism was based on the clinical picture, elevated free triiodothyronine (T 3 ) index (FT 3 I) and/or free thyroxine (T 4 ) index (FT 4 I), and suppressed serum thyrotropin level. Sixty-six patients received antithyroid drugs before 131 I treatment (propylthiouracil [n = 54], methimazole [n = 8], and carbimazole [n = 4]). In these patients, antithyroid drug treatment was discontinued 5 days before 131 I therapy and not resumed after 131 I treatment. Sixty-four patients did not receive antithyroid pretreatment. Pretreatment was based on the degree of hyperthyroidism and the clinical status of the patients.
Permanent hypothyroidism was defined as decreased FT 4 I accompanied by an elevated serum thyrotropin concentration. Euthyroidism was defined as FT 4 I and FT 3 I within the reference range. The 131 I dose was calculated as 3.7 MBq/g total thyroid mass (evaluated using ultrasound), corrected to 100% uptake of 131 I after 24 hours. The maximum single dose given was 740 MBq.
Serum concentrations of T 4 (reference range, 56-129 nmol/L [4-10 µg/dL]) and T 3 (reference range, 1.0-2.5 nmol/L) and T 3 resin uptake (reference range, 0.80-1.25 arbitrary units) were determined using in-house methods (assay variation was 6%, 10%, and 5%, respectively). The FT 4 I (reference range, 62-158 arbitrary units) and FT 3 I (reference range, 0.8-2.8 arbitrary units) were calculated as the total hormone concentration times the T 3 resin uptake. Serum concentrations of thyrotropin were determined using different commercial assays as described previously. 3 Ultrasonic scanning and calculation of total thyroid volume (reference range, 9.6-27.6 mL) was performed as previously described 18 using a compound scanner (type 3401 and type 1846; Brü el and Kjaer, Naerum, Denmark).
Thyroid function variables and the size of the thyroid on ultrasonography were determined before and 3 ⁄4, 1 1 ⁄2, 3, 6, and 12 months after treatment, and thereafter, once every year. In patients becoming hypothyroid, no further volume or thyroid function data were included in the data evaluation after hypothyroidism was diagnosed.
Results are given as median and range or 25th and 75th percentiles. When percentage of change in thyroid volume is used, the median values of the individual changes are given. For statistical evaluation, Wilcoxon test for paired design, Mann-Whitney test for unpaired design, 2 test, and life-table analysis were used. The level of significance was chosen as PϽ.05.
THYROID VOLUME IN PATIENTS RECEIVING ANTITHYROID PRETREATMENT
Median initial thyroid volume was 59 mL (16-430 mL). Twenty-five of the 66 patients were treated with more than 1 131 I dose. In these patients, 131 I doses not leading to euthyroidism caused a 27% decrease in thyroid volume from a median of 74 mL (21-430 mL) to 50 mL (13-315 mL) (PϽ.005), and 24 months after the last 131 I dose, a further decrease to 24 mL (8-108 mL) (PϽ.005). The median volume reduction after more than 1 131 I dose was 50%. Thyroid volume before and after 131 I therapy in relation to the latest 131 I dose is demonstrated in Figure 1 . A gradual 45% reduction from a median of 45 mL (13-315 mL) to 23 mL (8-120 mL) 24 months after treatment was observed (PϽ.005). Hereafter, no further significant changes were observed. Within the observation period, 11 patients became hypothyroid. In these patients, the median thyroid volume was reduced from 24 mL (17-66 mL) to 16 mL (8-72 mL) at the time when hypothyroidism was diagnosed (P = .01). Within the first 3 months after 131 I therapy, 68% of the total volume reduction was seen.
THYROID VOLUME IN PATIENTS NOT GIVEN ANTITHYROID PRETREATMENT
Median initial thyroid volume was 43 mL (18-125 mL). Twenty-four of the 64 patients were treated with more than 1 131 I dose. In these patients, 131 I doses not leading to euthyroidism caused a 21% decrease in thyroid volume from a median of 47 mL (23-125 mL) to 44 mL (15-99 mL) (P = .03), and 24 months after the last 131 I dose, a further decrease to 29 mL (8-76 mL) (PϽ.005). The median volume reduction after more than 1 131 I dose was 32%. Thyroid volume before and after 131 I therapy in relation to the latest 131 I dose is demonstrated in Figure 2 .
A gradual 40% reduction from a median of 43 mL (15-115 mL) to 27 mL (8-85 mL) 24 months after treatment was observed (PϽ.005). Hereafter, no further significant changes were observed. Within the observation period, 3 patients became hypothyroid. In these patients, the median thyroid volume was reduced from 19 mL (15-42 mL) to 10 mL (8-12 mL), measured at the time hypothyroidism was diagnosed. Within the first 3 months after 131 I therapy, 72% of the total volume reduction was seen.
There was no significant difference between the patients receiving and those not receiving antithyroid drug pretreatment in relation to changes in thyroid volume seen after the 131 I dose that cured the hyperthyroidism.
SIDE EFFECTS
Hypothyroidism occurred significantly more often in patients pretreated with antithyroid drugs (11/66 [17%]) than in those not receiving such treatment (3/64 [5%]) (P = .03). After evaluation using life-table analysis, hypothyroidism was seen in 14% of the entire group within 5 years. Hereafter, no further cases of hypothyroidism occurred. Life-table analysis showed a hypothyroidism rate of 20% within 5 years in patients treated with antithyroid premedication, whereas patients in the group not given antithyroid drug pretreatment had a significantly lower hypothyroidism rate of 6% (PϽ.005) (Figure 3) . Hypothyroidism was diagnosed after a median of 42 months (3-60 months). No significant differences in time to hypothyroidism, time to serum thyrotropin values greater than 4 µIU/mL, and time from these values to hypothyroidism were seen between patients who were given antithyroid drug pretreatment and those who were not ( Table 2 ). In Table 2 , 12 patients are described as having serum values of greater than 4 µIU/mL without progression to overt hypothyroidism. These patients had serum thyrotropin values in the range of 5 to 11 µIU/mL during follow-up (in 1 patient, a single measurement of 17 µIU/mL was found). In all patients, FT 4 I and FT 3 I were within the normal range, with no symptoms of hypothyroidism. Recurrence of hyperthyroidism after a longer period of euthyroidism without antithyroid drugs was seen in 1 patient treated with 400 MBq of 131 I. The patient was euthyroid with a slightly suppressed serum thyrotropin level for 10 years; then hyperthyroidism recurred and, after a further 131 I dose, the patient again became euthyroid.
None of the patients had symptoms of a radioiodine-induced thyroiditis. An increase (more than 5%) in thyroid volume was seen in 9 patients the first months after 131 I treatment. The median increase was 23% (11%-60%). In these 9 patients, the median thyroid volume was 33 mL (19-133 mL) before treatment. The largest increase was seen in a patient with an initial volume of 28 mL. None of these patients had increased pressure symptoms, and none needed surgical intervention. Three patients had a second 131 I dose, not because of compression symptoms, but because of continued hyperthyroidism.
In 1 patient, a disseminated follicular thyroid carcinoma was diagnosed 3 years after 131 I treatment of 488 MBq. The time from 131 I treatment to the diagnosis of a disseminated thyroid follicular cancer is too short to relate the cancer to the 131 I treatment.
COMMENT
The magnitude of thyroid volume reduction found in our study is of the same order as that seen after 131 I therapy in toxic diffuse 3 and autonomous solitary toxic thyroid adenomas 2,12 as well as in nontoxic diffuse 19, 20 and nontoxic multinodular goiter. 13 As in these long-term follow-up studies, 3, 12, 13 we found that the most pronounced reduction is seen within the first 3 months, with a continuous sizereducing effect of 131 I on thyroid volume lasting 2 years. One could speculate that if the 131 I is only taken up in the hyperfunctioning nodules, the reduction in the thyroid volume would be based on the changes in these nodules, leaving the paranodular tissue unaffected with a potential of growth. The result could be a primary reduction of the thyroid volume followed by a reincrease related to growth of the paranodular tissue. We did not see this secondary regrowth of the thyroid volume in a rather long follow-up, indicating that the 131 I affects not only the hyperfunctioning nodules but also the paranodular tissue. To our knowledge, these are the first long-term data on thyroid volume and function in multinodular toxic goiter, using an accurate thyroid size evaluation, and on 131 I therapy, taking thyroid size and 131 I uptake into consideration.
We demonstrated a cumulated risk for hypothyroidism of 14% within 5 years of 131 I therapy. No cases of hypothyroidism were seen beyond 5 years in this follow-up ranging from 1 to 15 years. This pattern of hypothyroidism is different from that seen in patients treated with 131 I for Graves disease. In the latter group, hypothyroidism was seen in approximately 20% within 1 year and thereafter with a constant incidence of 2% to 3% per year, eventually reaching 100% if the patients lived long enough. [3] [4] [5] In our study, the incidence of hypothyroidism is similar to that found in patients with other nonimmunological thyroid diseases such as autonomously functioning solitary thyroid nodules 11, 12 and nontoxic multinodular goiter. 13 Few published studies have addressed this issue in groups of patients all treated with 131 I for multinodular goiter. Franklyn et al 21 demonstrated hypothyroidism in 11.4% of 44 patients with a 1-year follow-up. Danaci et al 6 investigated 21 patients and found a cumulative 5-year hypothyroidism rate of 24%, giving a fixed dose of 444 MBq. Berg et al, 7 giving a calculated dose of 100 Gy, found that 47% were given thyroxine treatment 48 months after treatment. On the other hand, Wiener, 17 studying 88 patients only, found 1 patient with hypothyroidism in a follow-up ranging from 1 to 17 years (average, 5.3 years).
We found a significantly higher hypothyroidism rate in patients pretreated with antithyroid drugs (20%) compared with patients not given antithyroid premedication (6%). An explanation could be that in patients given antithyroid drugs before 131 I treatment, serum thyrotropin was not suppressed at the time of treatment, and the 131 I was taken up, not only in the hyperfunctioning nodules but in the whole thyroid gland. In a recent study, Hancock et al 22 found a significantly higher failure rate in patients treated with propylthiouracil until 4 to 7 days before 131 I therapy for Graves disease compared with patients not given anti- thyroid pretreatment, or patients whose therapy was discontinued for more than 1 week, suggesting that antithyroid drugs have a radioprotective effect. Corresponding results have been found by us and by others. 21, 23 In our study, we could not demonstrate a similar radioprotective effect of antithyroid pretreatment, as evidenced by a similar volume reduction in both groups as well as similar time to achieve euthyroidism and similar fraction of patients needing more than 1 dose of 131 I. However, the patients were not randomized to receive or not receive antithyroid pretreatment. The patients receiving antithyroid drug pretreatment were those with the most severe disease. To illuminate these questions, a randomized prospective study is warranted.
Using a relatively low dose of 131 I calculated according to 131 I uptake and thyroid volume, we found that 52% of our patients were cured within 3 months of therapy. This figure is lower than that found for Graves disease 3 and solitary autonomous thyroid nodules, 12 where cure rates of 75% are seen using corresponding doses. However, only 8 patients (6%) were not cured following this regimen. An increase in 131 I dose should theoretically reduce the number of initial failures and thus retreatment, reduce thyroid volume even more, and possibly lead to a higher incidence of hypothyroidism. Again, prospective studies are needed to substantiate this.
A potential major side effect of 131 I treatment is cancer, and several studies have addressed this question. [24] [25] [26] [27] [28] [29] [30] [31] [32] All of these studies conclude that there is no evidence of cancer induced by 131 I, when given in doses to treat benign thyroid diseases in adults. When 131 I treatment is given to patients with Graves disease, all thyroid cells receive a high amount of radiation, which reduces their ability to replicate. In nodular goiter, the paranodular tissue receives only small amounts of radiation, and it has recently been proposed that this tissue would be at risk for subsequent neoplastic transformation. 33 This hypothesis could be supported by the results of a 1998 study by Ron et al, 32 in which they found a small but statistically significant increase in thyroid cancer risk in patients with toxic nodular goiter. However, the major increase in mortality was seen in the first 5 years after treatment, indicating that the thyroid cancer was present before 131 I treatment. If this hypothesis was to be correct, one would also expect an increased number of thyroid cancers in patients examined with diagnostic doses of 131 I. It has not been possible to demonstrate such a correlation. 27 We saw a cure rate of 52% within 3 months after 1 131 I treatment for multinodular toxic goiter. One hundred nineteen patients (92%) were cured with 1 or 2 treatments. The median thyroid volume was reduced by 43%, and hypothyroidism was only seen in 14% within 5 years of treatment. Radioiodine, therefore, should be the treatment of choice in these patients.
